MOR 208

Drug Profile

MOR 208

Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; MOR-00208; MOR-208; XENP-5574; XmAb-5574

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Xencor
  • Developer MorphoSys; The Ohio State University Comprehensive Cancer Center; Xencor
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Diffuse large B cell lymphoma
  • Phase II Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Dec 2016 9208751- Updated kdm with dosing info in COSMOS trial
  • 02 Nov 2016 Morphosys plans to initiate the phase III portion of the phase II/III B-MIND trial for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in 2017
  • 01 Nov 2016 MorphoSys initiates enrolment in the phase II COSMOS trial for Chronic Lymphocytic Leukaemia in Austria, Germany, France and United Kingdom (NCT02639910; EudraCT2015-002915-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top